Psödo-Kaposi sarkomu klinik ve histopatolojik olarak Kaposi Psödo-Kaposi sarkomu histopatolojik ve klinik olarak anjiomatöz hastal›klarla. Request PDF on ResearchGate | Kaposi sarkomu nedeniyle radyoterapi uygulanan 14 hastanın değerlendirilmesi | Methods: The patients undergoing. English Turkish online dictionary Tureng, translate words and terms with different pronunciation options. kaposi’s sarcoma kaposi sarkomu kaposi’s sarcoma in.
|Genre:||Health and Food|
|Published (Last):||11 June 2009|
|PDF File Size:||20.93 Mb|
|ePub File Size:||10.35 Mb|
|Price:||Free* [*Free Regsitration Required]|
Kaposi’s sarcoma, a virus-associated neoplasm, can be treated with systemic therapy such interferon or chemotherapy, although a local alternative is possible in localized disease. Topical imiquimod is a ligand of the toll-like receptors 7 and 8 on dendritic cells, kappsi immune responses and showing antiviral and antitumoral activities.
Kaposi’s kqposi KS is a vascular neoplasm with four clinical subtypes: All variants have been related to the eighth human herpes virus HHV8 [ 1 ].
Therefore, topical imiquimod, an immune response modifier with antiangiogenic properties able to induce interferon-alpha secretion in situ, could prove a good local treatment for KS skin lesions [ 3 ].
The kapowi protocol consisted of 3 weekly applications Monday, Thursday, Saturday under occlusion for at least 10 hours between 10 and 12 hours. During the first week, the three applications were applied by the patient under supervision then the cream was self-administered for the following applications.
The tolerance was good with no side effects. After twenty weeks, the purple maculo-papular lesions cleared complete clinical response. Six months later the patient is still disease free.
Adverse events reported with imiquimod treatment include local side effects at the application site, ranging from mild erythema to weeping, crusting, and erosions. Systemic side effects are exceptional [ 5 ]. Concerning the literature, there are only two cases reports of KS treated by imiquimod and one phase II study.
After one year of therapy a complete response was observed and confirmed according to histopathology and immunohistochemistry.
The treatment was well tolerated, and the only significant side effects were flu-like symptoms that disappeared with the reduction of the dosage. After more than one year of follow-up, the patient was still disease-free. The tolerance was good with only transient itching and flu-like symptoms. The phase II trial was conducted by a French team, and 17 patients were enrolled for classic or endemic KS. Tumor progression was noted in 6 patients. For all the patients, there were no clinically meaningful changes from baseline in any of kapoei laboratory test values, physical examinations, or vital sign measurements during the course of the study.
There were no treatment-related deaths or serious adverse events.
Immunocompetent patients with new and small skin lesions seem to be ideal patients for treatment by topical imiquimod. Imiquimod cream offers an attractive alternative to locally destructive therapies, with less risk of pain, ulceration, and residual scarring. Furthermore, imiquimod can be applied by the patient. Topical imiquimod seems to be a good local treatment for Kaposi’s sarcoma skin lesions sadkomu a good toxicity profile, regimens with daily application may offer best clinical results and should be explored and evaluated concerning the toxicity.
Written informed consent was obtained from the patient for the publication of this case. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Kaposi’s sarcoma responding to topical imiquimod 5% cream: a case report
The authors have indicated no significant interest with commercial supporters. SB and BS interpreted the patient data regarding the disease history and contributed to the literature research.
Ksposi Center for Biotechnology InformationU. Journal List Cases J v. Published online Sep Author information Article notes Copyright and License information Disclaimer.
Received Apr 6; Accepted Aug This article has been cited by other articles in PMC. Abstract Kaposi’s sarcoma, a virus-associated neoplasm, can be treated with systemic therapy such interferon or chemotherapy, although a local alternative is possible in localized disease.
Introduction Kaposi’s sarcoma KS is a vascular neoplasm with four clinical subtypes: Conclusion Topical imiquimod seems to be a good local treatment for Kaposi’s sarcoma skin lesions with a good toxicity profile, regimens with daily application may offer best clinical results and should be explored and evaluated concerning the toxicity.
Consent Written informed consent was obtained from the patient for the publication of this case. Competing interests The authors have indicated no significant interest with commercial supporters. Authors’ contributions SB and BS interpreted the patient data regarding the disease history and contributed to the literature sarkmu. Update on Kaposi’s sarcoma. Med Trop Mars ; Update on classic Kaposi sarcoma therapy: New look at an old disease. Crit Rev Oncol Hematol. Immunomodulatory and pharmacologic properties of imiquimod.
Tureng – kaposi sarkomu – Turkish English Dictionary